Search Results

Pathos AI licenses first-in-class bispecific ADC JSKN016 from Alphamab Oncology in deal worth up to $4.8 billion Pathos AI has entered a global licensing agreement with Alphamab Oncology for JSKN016, a first-in-class TROP2/HER3 bispecific antibody-drug conjugate (ADC), paying $200 million upfront in a deal that could be worth up to $4.8 billion if development, regulatory and commercial milestones are achieved. The transaction adds a differentiated clinical-stage oncology asset to Pathos AI's pipeline while enabling Alphamab Oncology to retain Greater China rights and participate in the programme's long-term commercial success through milestone payments and royalties. Field Content Alert Type Deal Companies Pathos AI; Alphamab Oncology Deal Type Global licensing agreement Asset or Company JSKN016, a first-in-class TROP2/HER3 bispecific antibody-drug conjugate (ADC) Therapy Area(s) Oncology; Solid tumours Technology or Modality Bispecific antibody-drug conjugate (ADC) Deal Value $200 million upfront, with potential development, regulatory and commercial milestone payments bringing the total value to up to $4.8 billion, plus tiered royalties on future net sales. Development Stage Phase I/II Geography Global excluding Greater China (Alphamab Oncology retains Greater China rights) What Happened On 5 August 2026, Pathos AI announced a global licensing agreement with Alphamab Oncology for exclusive rights outside Greater China to develop, manufacture and commercialise JSKN016. Pathos AI will pay $200 million upfront and may make additional milestone payments of up to $4.6 billion, together with tiered royalties on net sales. Alphamab Oncology retains rights in Greater China while both companies will collaborate on technology transfer and ongoing development activities. Why It Matters The agreement provides Pathos AI with a clinical-stage bispecific ADC targeting both TROP2 and HER3, expanding its precision oncology portfolio with a novel modality that could have potential across multiple solid tumours. For Alphamab Oncology, the partnership provides significant non-dilutive capital while retaining regional commercial rights and future economic participation outside Greater China. Supporting Context JSKN016 is designed to target both TROP2 and HER3, two proteins frequently expressed across a range of epithelial cancers. Early clinical studies are evaluating the candidate in patients with advanced solid tumours, where bispecific ADCs are being explored as a strategy to improve tumour targeting while broadening therapeutic activity. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The approval adds another US biosimilar option for rituximab-treated conditions, including non-Hodgkin lymphoma and chronic lymphocytic leukaemia, although commercial availability and pricing have not yet been confirmed. The US Food and Drug Administration has approved Reditux, Dr. Reddy’s Laboratories’ rituximab biosimilar referencing Rituxan, for the reference product’s eligible haematological malignancy and autoimmune disease indications. The approval expands the number of rituximab biosimilars available to US clinicians and patients, with Fresenius Kabi holding exclusive US commercialisation rights. Field Content Alert Type Drug Approval Drug Name Reditux (rituximab biosimilar) Indication Eligible indications of the reference product Rituxan, including CD20-positive non-Hodgkin lymphoma, CD20-positive chronic lymphocytic leukaemia, rheumatoid arthritis, granulomatosis with polyangiitis, microscopic polyangiitis and pemphigus vulgaris. Therapy Area(s) Haematology; Oncology; Rheumatology; Immunology Geography United States (FDA) What Happened On 1 August 2026, the FDA approved Reditux, Dr. Reddy's Laboratories' rituximab biosimilar referencing Rituxan. The approval was supported by analytical, non-clinical and clinical evidence demonstrating no clinically meaningful differences from the reference product in terms of safety, purity and potency. Fresenius Kabi holds exclusive commercialisation rights for the product in the United States. Why It Matters The approval provides healthcare providers with another rituximab biosimilar across multiple oncology and autoimmune indications, potentially increasing treatment choice and supporting biosimilar competition. However, FDA approval alone does not determine pricing, reimbursement, formulary inclusion or uptake in clinical practice. Supporting Context Rituximab is a CD20-directed monoclonal antibody widely used in B-cell malignancies and several autoimmune diseases. Reditux has previously been marketed in India and approved in numerous international markets before receiving FDA approval. Key Takeaway FDA approval adds another rituximab biosimilar to the US market, expanding treatment options across approved oncology and autoimmune indications. What to Watch Commercial launch timing, payer coverage, formulary adoption and pricing will determine how quickly Reditux becomes available to US clinicians and patients. Primary Source https://www.drreddys.com/cms/sites/default/files/2026-08/20260801_PressRelease_rituximab_SE.pdf Relevant Date 1 August 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The biomarker-selected regimen adds an AKT inhibitor to abiraterone and prednisone for adults with newly diagnosed metastatic disease whose tumours show PTEN deficiency. The US Food and Drug Administration has approved Truqap (capivasertib) with abiraterone and prednisone for adults with PTEN-deficient metastatic androgen pathway modulation-naïve or -sensitive prostate cancer, previously referred to as metastatic hormone-sensitive prostate cancer. The expanded indication provides a new targeted combination for a molecularly defined patient group, although treatment requires FDA-authorised PTEN testing and monitoring for toxicities including hyperglycaemia, diarrhoea and cutaneous reactions. Field Content Alert Type Drug Approval Drug Name Truqap (capivasertib) Indication In combination with abiraterone and prednisone for adults with metastatic androgen pathway modulation-naïve or -sensitive prostate cancer that is PTEN-deficient, as detected by an FDA-authorised test. Therapy Area(s) Oncology; Prostate cancer Geography United States (FDA) What Happened On 12 June 2026, the FDA expanded Truqap’s approval to include capivasertib with abiraterone and prednisone for adults with PTEN-deficient metastatic androgen pathway modulation-naïve or -sensitive prostate cancer. The agency also approved the VENTANA PTEN (SP218) RxDx Assay as a companion diagnostic for identifying eligible patients. Truqap was previously approved in combination with fulvestrant for a biomarker-defined population with advanced breast cancer. (U.S. Food and Drug Administration) Why It Matters PTEN deficiency is used to identify patients whose disease may be appropriate for this AKT-targeted combination, introducing a biomarker-directed option earlier in the metastatic prostate cancer pathway. In CAPItello-281, the regimen improved radiographic progression-free survival compared with abiraterone and placebo, but overall survival data were immature at the time of the analysis and the additional toxicity burden requires active clinical management. (U.S. Food and Drug Administration) Supporting Context CAPItello-281 enrolled 1,012 adults with newly diagnosed PTEN-deficient disease. Median radiographic progression-free survival was 33.2 months with capivasertib and abiraterone versus 25.7 months with placebo and abiraterone, corresponding to a hazard ratio of 0.81. (U.S. Food and Drug Administration) Key Takeaway The approval adds a PTEN-selected targeted regimen for metastatic hormone-sensitive prostate cancer, with eligibility dependent on companion diagnostic testing. What to Watch Mature overall survival findings from CAPItello-281 and how routinely PTEN testing is incorporated into treatment selection for newly diagnosed metastatic disease. Primary Source https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-capivasertib-abiraterone-and-prednisone-pten-deficient-androgen-pathway-modulation Relevant Date 12 June 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Recent legal and regulatory developments could influence how innovative medicines are protected in Europe by changing the interaction between regulatory exclusivity, patent rights and generic market entry. The EU General Court has annulled a European Commission decision that granted Biogen an additional year of market protection for Tecfidera, while policymakers continue to advance the EU Pharmaceutical Package, which would reform regulatory exclusivity and broaden Bolar exemptions. Together, these developments highlight the growing interaction between regulatory protection and intellectual property strategy for pharmaceutical companies developing and commercialising medicines in Europe. Field Content Alert Type Industry Update Topic Pharmaceutical regulation and intellectual property Organisation(s) EU General Court; European Commission; Council of the European Union Affected Stakeholders Originator pharmaceutical companies, generic and biosimilar manufacturers, biotechnology companies and intellectual property professionals Geography European Union What Happened The EU General Court confirmed that the conditions for obtaining an additional year of market protection under Article 14(11) of Regulation (EC) No 726/2004 must be applied strictly by annulling the European Commission's decision granting Biogen extended protection for Tecfidera. Separately, the EU's proposed Pharmaceutical Package continues to progress through the legislative process, introducing reforms to regulatory exclusivity, market protection and the scope of the Bolar exemption, although the legislation has not yet been formally adopted and will be subject to a transitional implementation period. (Osborne Clarke) Why It Matters These developments reinforce that regulatory exclusivity and patent protection operate together but under separate legal frameworks. Pharmaceutical companies may need to reassess lifecycle management, market-entry planning, patent enforcement and generic launch strategies as the regulatory environment evolves. (Osborne Clarke) Supporting Context The Tecfidera judgment illustrates how decisions affecting regulatory exclusivity can directly influence commercial timelines for innovative medicines. At the same time, the proposed Pharmaceutical Package would shorten and condition certain exclusivity periods while expanding activities permitted under the Bolar exemption before generic or biosimilar launch. (Osborne Clarke) Who Is Most Affected Pharmaceutical companies managing European product lifecycles, together with generic and biosimilar developers planning market entry, are likely to experience the greatest impact because both regulatory protection and patent strategy influence launch timing and competitive positioning. (Osborne Clarke) Industry Impact If adopted in its current form, the pharmaceutical reforms could alter how companies balance regulatory incentives with patent portfolios, requiring earlier planning for lifecycle management, intellectual property strategy and competition from generic and biosimilar medicines. The practical impact will depend on the final legislative text and national implementation. (Osborne Clarke) Key Takeaway Regulatory exclusivity and patent protection are becoming increasingly interconnected strategic considerations for companies operating in the European pharmaceutical market. (Osborne Clarke) What to Watch Formal adoption of the EU Pharmaceutical Package, publication in the Official Journal, the subsequent two-year transition period and future case law interpreting both the revised exclusivity framework and UPC pharmaceutical patent disputes. (Osborne Clarke) Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Healthcare organisations and technology developers face an expanding mix of state laws, sector-specific FDA expectations and federal policy initiatives rather than a single nationwide AI regulatory framework. A new analysis argues that declining public trust, cybersecurity risks, commercial pressure and state-level legislative activity are increasing the likelihood of further US artificial intelligence oversight, although Congress has not enacted a comprehensive federal AI law. For healthcare stakeholders, the immediate challenge is managing existing state requirements and FDA expectations while preparing for possible national standards that could affect clinical AI development, procurement, transparency and ongoing performance monitoring. Field Content Alert Type Industry Update Topic Artificial intelligence regulation and healthcare technology Organisation(s) US federal government; US Food and Drug Administration; state legislatures Affected Stakeholders Healthcare AI developers, medical-device manufacturers, health systems, clinicians procuring or using AI tools, and organisations deploying automated decision systems Therapy Area(s) Industry-wide Geography United States What Happened An analysis published on 1 August 2026 identified public concern, cybersecurity threats, commercial pressure, political momentum and US competition for global AI leadership as factors that could drive further federal oversight. No comprehensive federal AI statute has been enacted: current governance instead consists of federal executive policy, sector-specific agency activity and an expanding patchwork of state laws. In healthcare, the FDA has already issued draft lifecycle guidance for AI-enabled medical devices and maintains a regularly updated list of authorised AI-enabled products, while the White House’s AI Action Plan prioritises innovation and the removal of regulatory barriers alongside monitoring emerging risks. (Forbes) Why It Matters Healthcare organisations cannot wait for a single federal AI Act before addressing compliance. Developers and providers may already need to consider medical-device regulation, validation, bias, transparency, cybersecurity and post-market performance, while also accounting for differing state requirements. Any future national framework could reduce regulatory fragmentation, but its obligations and relationship with state law remain uncertain. (U.S. Food and Drug Administration) Supporting Context The White House’s July 2025 AI Action Plan promotes private-sector innovation, AI infrastructure and US leadership while opposing regulation considered unnecessarily burdensome. At the same time, state lawmakers have continued to pursue rules covering areas such as high-risk automated decisions, transparency, employment and healthcare, creating practical compliance duties despite the lack of an overarching federal law. (The White House) Who Is Most Affected Medical-device companies and digital-health developers face the clearest immediate exposure because AI functions that meet the definition of a medical device remain subject to FDA premarket requirements and lifecycle expectations. Health systems and clinicians are also affected when evaluating whether tools are authorised, appropriately validated and suitable for specific patient populations and clinical workflows. (U.S. Food and Drug Administration) Industry Impact The evolving framework could increase demand for formal AI governance, product documentation, risk assessment, bias evaluation, human oversight and post-deployment monitoring across healthcare organisations. However, the eventual extent of federal intervention remains unclear, particularly given the administration’s stated preference for innovation-led and minimally burdensome regulation. (The White House) Key Takeaway US healthcare AI oversight is already developing through agency guidance and state legislation, even though a comprehensive federal regulatory framework has not been adopted. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The expanded indication moves radioligand therapy into an earlier stage of metastatic prostate cancer, providing an additional treatment option for eligible patients before progression to castration-resistant disease. The US Food and Drug Administration (FDA) has approved Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) in combination with an androgen receptor pathway inhibitor (ARPI) for adults with prostate-specific membrane antigen (PSMA)-positive metastatic androgen pathway modulation-naïve or -sensitive prostate cancer, previously referred to as metastatic hormone-sensitive prostate cancer. The approval expands Pluvicto's use into an earlier treatment setting, offering eligible patients a radioligand therapy alongside standard systemic treatment before progression to metastatic castration-resistant disease. Field Content Alert Type Drug Approval Drug Name Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) Indication In combination with an androgen receptor pathway inhibitor for adults with PSMA-positive metastatic androgen pathway modulation-naïve or -sensitive prostate cancer. Patients should be selected using Locametz® (gallium Ga 68 gozetotide) or another FDA-approved PSMA PET imaging agent. (U.S. Food and Drug Administration) Therapy Area(s) Oncology; Prostate Cancer Geography United States (FDA) What Happened On 31 July 2026, the FDA approved Pluvicto in combination with an ARPI for adults with PSMA-positive metastatic androgen pathway modulation-naïve or -sensitive prostate cancer. The decision expands Pluvicto's existing indication beyond metastatic castration-resistant prostate cancer into an earlier metastatic treatment setting and is based on results from the Phase III PSMAddition trial. (U.S. Food and Drug Administration) Why It Matters The approval enables eligible patients to receive targeted radioligand therapy earlier in the course of metastatic disease while continuing standard androgen receptor pathway inhibition. It broadens treatment options for PSMA-positive disease, although appropriate patient selection remains dependent on PSMA PET imaging and long-term overall survival data are still maturing. (U.S. Food and Drug Administration) Supporting Context In the PSMAddition trial, Pluvicto plus standard of care reduced the risk of radiographic progression or death compared with ARPI-based standard therapy alone. Overall survival data were immature at the time of approval, although an encouraging trend was reported. (U.S. Food and Drug Administration) Key Takeaway FDA approval extends Pluvicto into the metastatic hormone-sensitive setting, introducing radioligand therapy earlier in the treatment pathway for eligible patients with PSMA-positive disease. (U.S. Food and Drug Administration) What to Watch Longer-term overall survival results from PSMAddition and how rapidly PSMA PET-guided patient selection is incorporated into routine first-line metastatic prostate cancer care. (U.S. Food and Drug Administration) Primary Source https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lutetium-lu-177-vipivotide-tetraxetan-androgen-receptor-pathway-inhibitor-therapy Relevant Date 31 July 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The updated vaccine is authorised for individuals aged six months and older and aligns the EU COVID-19 vaccination programme with the currently circulating XFG variant. The European Commission has authorised the Pfizer-BioNTech XFG-adapted COVID-19 vaccine for active immunisation against COVID-19 in individuals aged six months and older across the European Union, Iceland, Liechtenstein and Norway, following a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP). The approval updates the vaccine composition for the 2026–2027 respiratory season, supporting continued protection against the currently circulating XFG variant while maintaining the established mRNA vaccine platform. Field Content Alert Type Drug Approval Drug Name Pfizer-BioNTech XFG-adapted COVID-19 vaccine (COMIRNATY®, COVID-19 Vaccine, mRNA) Indication Active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals aged six months and older. (Pfizer) Therapy Area(s) Infectious Diseases; Vaccines Geography European Union (European Commission) What Happened On 29 July 2026, the European Commission granted marketing authorisation for the Pfizer-BioNTech XFG-adapted COVID-19 vaccine for the 2026–2027 vaccination season. The updated formulation targets the XFG variant of the JN.1 lineage following the EMA Emergency Task Force recommendation and is authorised for active immunisation in individuals aged six months and older throughout all EU Member States, as well as Iceland, Liechtenstein and Norway. This updates the existing marketing authorisation with a revised seasonal vaccine formulation rather than representing a first approval. (Pfizer) Why It Matters The authorisation ensures healthcare providers have an updated COVID-19 vaccine aligned with the variants expected to circulate during the 2026–2027 respiratory season. Updating vaccine composition in response to viral evolution is intended to maintain vaccine relevance, although uptake and public health impact will depend on national vaccination programmes and recommendations. (Pfizer) Supporting Context The approval follows the CHMP's positive opinion issued on 23 July 2026 and the EMA Emergency Task Force recommendation to target the XFG variant after reviewing available epidemiological and immunogenicity data. Pfizer and BioNTech stated that manufacturing had already begun to support vaccine availability ahead of the respiratory virus season. (Pfizer) Key Takeaway The European Commission has authorised an updated Pfizer-BioNTech COVID-19 vaccine targeting the XFG variant, enabling deployment of the 2026–2027 seasonal formulation across the EU. (Pfizer) What to Watch National vaccination recommendations, country-level procurement and rollout schedules, and regulatory decisions in other jurisdictions will determine when the updated vaccine becomes available to eligible populations. (Pfizer) Primary Source https://www.pfizer.com/news/press-release/press-release-detail/european-commission-authorizes-pfizer-and-biontech-xfg Relevant Date 29 July 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The two regulatory decisions could expand first-line treatment options for patients with ESR1-mutant ER-positive disease and HER2-positive metastatic breast cancer, although Enhertu still requires European Commission approval. The European Commission has approved Etcamah (camizestrant) with a CDK4/6 inhibitor for adults with ESR1-mutant, ER-positive, HER2-negative locally advanced or metastatic breast cancer whose disease has not progressed during first-line endocrine therapy, while the EMA’s CHMP has recommended Enhertu (trastuzumab deruxtecan) with pertuzumab for first-line unresectable or metastatic HER2-positive breast cancer. Etcamah introduces a biomarker-triggered treatment switch before clinical progression, whereas the Enhertu combination could provide a new first-line option if the Commission endorses the CHMP opinion. Field Content Alert Type Drug Approval Drug Name Etcamah (camizestrant); Enhertu (trastuzumab deruxtecan) in combination with pertuzumab Indication Etcamah with palbociclib, ribociclib or abemaciclib: adults with ER-positive, HER2-negative locally advanced or metastatic breast cancer upon detection of an ESR1 mutation and without disease progression during first-line endocrine therapy with a CDK4/6 inhibitor. Enhertu with pertuzumab: proposed first-line treatment of adults with unresectable or metastatic HER2-positive breast cancer. (ema.europa.eu) Therapy Area(s) Oncology; Breast cancer Geography European Union — European Commission and EMA Committee for Medicinal Products for Human Use What Happened The European Commission granted marketing authorisation for Etcamah on 20 July 2026, following the CHMP’s positive opinion in May. The approval permits clinicians to replace the aromatase-inhibitor component of first-line therapy with camizestrant when an ESR1 mutation is detected, while continuing the existing CDK4/6 inhibitor. Separately, on 23 July 2026, the CHMP recommended extending Enhertu’s authorisation to include its use with pertuzumab as first-line therapy for unresectable or metastatic HER2-positive breast cancer; this is a recommendation rather than a final EU approval. (ema.europa.eu) Why It Matters Etcamah provides a treatment strategy based on detecting emerging endocrine resistance before radiological disease progression, offering eligible patients an alternative endocrine backbone while retaining their CDK4/6 inhibitor. The Enhertu opinion could move the antibody–drug conjugate into the first-line setting, where taxane, trastuzumab and pertuzumab has remained a standard approach for more than a decade, but clinical use in this setting depends on a final Commission decision. (ema.europa.eu) Supporting Context In SERENA-6, median progression-free survival was approximately 17 months with Etcamah plus a CDK4/6 inhibitor versus around nine months when patients continued letrozole or anastrozole with the inhibitor. In DESTINY-Breast09, Enhertu plus pertuzumab produced median progression-free survival of 40.7 months versus 26.9 months with taxane, trastuzumab and pertuzumab, with no new safety concerns identified by the companies. (ema.europa.eu) Key Takeaway The Etcamah approval and Enhertu recommendation advance two distinct biomarker-led first-line strategies for advanced breast cancer in Europe. What to Watch The European Commission’s final decision on the Enhertu–pertuzumab indication and the implementation of ESR1 mutation monitoring to identify patients eligible for an Etcamah treatment switch. Primary Source https://ec.europa.eu/health/documents/community-register/2026/20260720170116/dec_170116_en.pdf; https://www.ema.europa.eu/en/medicines/human/variation/enhertu Relevant Date 23 July 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The approval introduces the first immunotherapy combination for BCG-naïve high-risk non-muscle-invasive bladder cancer, marking a potential shift in the standard of care. The FDA has approved AstraZeneca’s Imfinzi (durvalumab) in combination with Bacillus Calmette-Guérin (BCG) for adults with BCG-naïve, high-risk non-muscle-invasive bladder cancer (NMIBC), becoming the first immunotherapy-based combination approved in this setting. The decision was supported by Phase III POTOMAC trial data showing a 32% reduction in the risk of disease recurrence, progression, or death compared with BCG alone. With more than five years of follow-up, the Imfinzi regimen delivered sustained disease-free survival benefits while maintaining a safety profile consistent with the individual therapies, reinforcing its potential to establish a new treatment benchmark for high-risk NMIBC patients. Alert Type Regulatory Approval (FDA) Drug/Device Name Imfinzi (durvalumab) + Bacillus Calmette-Guérin (BCG) Indication BCG-naïve, high-risk non-muscle-invasive bladder cancer (NMIBC) in adults Therapy Area(s) Oncology, Urology, Bladder Cancer, Immuno-oncology Geography United States (FDA approval) What Changed The FDA approved AstraZeneca’s Imfinzi (durvalumab) in combination with BCG induction and maintenance therapy for adults with BCG-naïve, high-risk NMIBC. Based on the Phase III POTOMAC trial, the combination reduced the risk of high-risk disease recurrence, progression, or death by 32% compared with BCG alone, becoming the first approved immunotherapy combination in this setting. Clinical Relevance The approval introduces a new treatment paradigm for high-risk NMIBC by adding immunotherapy to the long-established BCG backbone. The regimen demonstrated durable disease-free survival benefits over more than five years of follow-up while maintaining a manageable safety profile, preserving BCG treatment completion rates, and not negatively affecting patient-reported quality of life. Source Link https://www.globaldata.com/newsletter/details/fda-approves-astrazeneca-s-imfinzi-bcg-combination-for-nmibc-therapy_383859/ Date 1-Jun-2026 Status Draft Notes POTOMAC Phase III data showed a disease-free survival hazard ratio of 0.68 with a median follow-up of 60.7 months. No new safety signals were identified versus the known profiles of Imfinzi and BCG. Regulatory reviews are ongoing in the EU, Japan, and other markets. The approval further expands Imfinzi’s role across the bladder cancer treatment pathway alongside ongoing Phase III programmes including VOLGA, NIAGARA, and NILE. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The US Food and Drug Administration (FDA) has approved a combination regimen of Merck & Co.’s Keytruda (pembrolizumab) and Welireg (belzutifan) for the adjuvant treatment of adults with clear cell renal cell carcinoma (ccRCC) at risk of recurrence following surgery. The decision also extends to Keytruda Qlex, a subcutaneous formulation of the anti–PD-1 therapy (pembrolizumab/berahyaluronidase alfa-pmph), marking another step in Merck’s strategy to broaden Keytruda’s delivery formats and lifecycle. Phase III data underpinning approval The approval follows a priority review and is based on the Phase III LITESPARK-022 trial, which enrolled 1,841 patients who had undergone nephrectomy and were classified as intermediate-high or high risk of recurrence, or had resected metastatic disease with no evidence of active cancer. Patients were randomised to receive either Welireg plus Keytruda or Keytruda plus placebo in the adjuvant setting. At a prespecified interim analysis, the combination demonstrated a 28% improvement in disease-free survival (DFS), defined as time to recurrence, metastasis or death. There were 186 DFS events in the combination arm compared with 246 in the control group. Median DFS was not reached in either arm, and overall survival data remain immature. Expanding Welireg’s role in renal cell carcinoma Welireg (belzutifan), a HIF-2α inhibitor, already carries an indication in kidney cancer following its 2023 approval for previously treated advanced renal cell carcinoma patients who had received PD-(L)1 and VEGF-targeted therapies. The latest approval moves the therapy further upstream into the post-surgical adjuvant setting, reinforcing Merck’s intent to build a multi-line renal cancer franchise spanning both immunotherapy and targeted hypoxia pathways. Keytruda’s growing footprint in kidney cancer This marks Keytruda’s fourth approved indication in renal cell carcinoma. Earlier approvals include first-line advanced settings in combination with Pfizer’s Inlyta (axitinib) and Eisai’s Lenvima (lenvatinib), as well as a post-nephrectomy indication based on the KEYNOTE-564 study, where Keytruda demonstrated a 38% improvement in overall survival in high-risk patients. Taken together, these approvals consolidate Keytruda as a central backbone therapy across multiple stages of kidney cancer treatment. Competitive backdrop remains unresolved Despite the expanding evidence base for Keytruda-based combinations, treatment selection in renal cell carcinoma remains highly competitive. Some clinical experts continue to favour Bristol Myers Squibb’s Opdivo (nivolumab)-based combinations, citing ongoing uncertainty around optimal sequencing and long-term comparative outcomes across immuno-oncology regimens. This leaves the field open, with multiple checkpoint inhibitor combinations still competing for long-term dominance in both advanced and adjuvant kidney cancer settings. Outlook The Welireg–Keytruda approval strengthens Merck’s position in renal oncology by combining immunotherapy with targeted hypoxia biology in a high-risk post-surgical population. While the immediate clinical impact will depend on uptake and sequencing preferences, the broader strategic signal is clear: Merck is continuing to build depth across multiple mechanisms in kidney cancer rather than relying on single-agent dominance. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The Medscape General Surgeon Compensation Report 2026 shows general surgery remains one of the higher-paying physician specialties, with compensation continuing to rise during 2025. General surgeons reported average compensation of approximately $442,000, with earnings increasing by around 2% year-over-year. While growth was slightly below the physician average, general surgery continues to sit comfortably among the better-compensated specialties in medicine. However, as with many procedural disciplines, compensation outcomes are becoming increasingly influenced by productivity and practice structure rather than experience alone. The biggest differences are no longer created by how long you have been practising. They are increasingly determined by volume, efficiency and the type of surgical practice you operate within. General surgery compensation continues to rise The Medscape 2026 data shows general surgeons experienced compensation growth of approximately 2% during 2025. While this sits slightly below: The physician average of 3% Core inflation of 2.7% It still represents continued earnings growth within a highly competitive specialty. What this means in real terms: General surgery remains financially resilient. Compensation continues to increase, even if growth is more modest than some of the highest-performing specialties. The more important question is: Where do you sit within the general surgery earnings distribution? Because surgical volume, productivity and practice structure increasingly determine compensation outcomes. Below the general surgery earnings range This group sits below the specialty's main compensation cluster. This typically reflects: Lower surgical volumes Early-career positions Employed hospital-based roles Reduced productivity incentives Limited private practice exposure What this means in real terms: You may still earn significantly above many physician specialties. However, you currently sit below the earnings level being generated by much of the general surgery market. Around the general surgery earnings range This is where much of the specialty sits. Compensation here is typically driven by: Consistent surgical activity Stable patient demand Standard productivity levels A balanced mix of operative and clinical work This represents the functional centre of general surgery earnings in 2026. Above the general surgery earnings range This is where compensation begins to separate from the wider distribution. Higher earners are often characterised by: High surgical throughput Strong productivity performance Greater procedural volumes Private practice exposure Leadership or ownership responsibilities At this level, practice structure becomes a more important driver than experience alone. 51% of general surgeons feel fairly compensated Despite strong earnings relative to many specialties, only 51% of general surgeons reported feeling fairly compensated. While this is an improvement on previous findings, it remains far from universal satisfaction. What this means: Compensation alone does not determine how surgeons feel about their careers. Two surgeons earning similar incomes may experience very different levels of satisfaction depending on: Workload intensity On-call commitments Administrative burden Staffing support Operating theatre access Compensation and career satisfaction remain closely linked, but they are not the same thing. Expectations remain mixed The report shows: 37% expect compensation increases 39% expect flat pay 24% expect compensation declines What this means in real terms: The outlook remains positive overall, but less optimistic than some specialties. A significant proportion of surgeons still expect earnings growth. However, almost one-quarter anticipate lower compensation, reflecting ongoing concerns around reimbursement pressures and practice costs. Incentives remain heavily tied to productivity Among general surgeons eligible for incentive compensation: RVU generation remains the leading bonus driver What this means: General surgery continues to operate within a highly productivity-driven compensation model. The report also found that 43% of surgeons now have RVUs influencing base pay, not just bonus compensation. This places measurable output at the centre of many compensation structures. For high-performing surgeons, this creates substantial upside potential. For others, it can widen earnings differences across the specialty. What this means for you by experience level If you are early career (0–3 years post-consultant) At this stage, future earning potential matters more than current compensation. If you are: Below the specialty range, you are still building surgical volume and experience Around the range, you are progressing in line with typical general surgery outcomes Above the range, you may have entered a high-volume practice environment early Key point: Early-career progression is heavily influenced by access to operative opportunities. If you are mid-career (4–9 years) This is where compensation differences begin to emerge. What the report suggests: Most surgeons cluster around the specialty average Higher earners increasingly separate through productivity and procedural volume If you are: Below the range, you sit beneath the specialty benchmark Around the range, you reflect typical general surgery outcomes Above the range, you are benefiting from volume and structural advantages Key insight: This is where productivity begins to matter as much as experience. If you are established (10–19 years) At this stage, earnings divergence becomes increasingly visible. What the report shows: A stable middle exists, but a higher-income tier emerges for surgeons with stronger productivity profiles and greater practice leverage. If you are: Below the range, you sit below the specialty benchmark Around the range, you align with the core distribution Above the range, you are capturing a larger share of surgical income opportunities Key point: The financial gap between groups becomes increasingly meaningful. If you are senior (20+ years) At the senior level, compensation typically follows one of two paths: Stable earnings supported by established surgical practice and referral networks Continued growth driven by productivity, leadership positions and practice ownership The distinction increasingly comes down to structure rather than tenure. The core message of the 2026 report The Medscape 2026 general surgery data can be reduced to three anchors: Average compensation sits at approximately $442,000 51% feel fairly compensated 37% expect further earnings growth Taken together, the picture is clear: General surgery remains one of the better-paid physician specialties and continues to generate modest compensation growth. However, individual outcomes are increasingly influenced by productivity and practice structure rather than experience alone. Summary If you are a general surgeon reading this report, the key question is not whether compensation continues to rise. It is the more important question: Am I positioned to maximise the opportunities available within today's surgical compensation models? Because the report makes one thing clear: General surgery remains financially strong, but your place within the earnings distribution is increasingly determined by productivity, volume and practice structure rather than years in practice alone. Source Medscape General Surgeon Compensation Report 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The deal gives Vertex access to a commercial acromegaly therapy and a late-stage rare disease pipeline as the company diversifies beyond cystic fibrosis. Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals in a transaction valued at approximately $10 billion, marking the company’s largest acquisition to date. Under the terms of the agreement, Vertex will acquire Crinetics for $85 per share, with the transaction expected to close in the third quarter of 2026. The acquisition strengthens Vertex’s position in rare diseases by adding an established endocrinology portfolio, including Palsonify (paltusotine), an oral therapy approved in the US and EU for adults with acromegaly. Expanding Beyond Cystic Fibrosis Vertex built its commercial success around cystic fibrosis, with its franchise generating more than $11 billion in revenue in 2025. The company has used that financial strength to expand into additional therapeutic areas, including gene therapy, pain management and kidney disease. However, some newer growth areas have faced challenges. The company’s non-opioid pain medicine Journavx (suzetrigine) gained approval as the first new non-opioid pain treatment in more than two decades. Still, expectations for broader chronic pain adoption have remained limited. Meanwhile, uptake of Vertex’s gene therapy, Casgevy (exagamglogene autotemcel), has been affected by challenges common to cell and gene therapies, including high costs, reimbursement barriers, and complex treatment pathways. The Crinetics acquisition provides Vertex with a commercial product and a pipeline focused on rare endocrine disorders. Palsonify Provides Immediate Commercial Opportunity The centrepiece of the deal is Palsonify (paltusotine), an oral non-peptide somatostatin receptor type 2 (SST2) agonist designed to treat acromegaly. The therapy was approved in the US and EU as a first-line treatment for adults with acromegaly, a rare hormonal disorder caused by excess growth hormone production. Since launching in the US in late 2025, Palsonify has generated approximately $15.7 million in net product revenue. Vertex said early performance reflects strong demand, expanding prescribing activity and increasing reimbursement coverage. Vertex CEO Reshma Kewalramani said the company’s experience commercialising rare disease medicines would help accelerate the drug’s growth following the acquisition. Building a Rare Endocrinology Pipeline Beyond Palsonify, the acquisition adds Crinetics’ clinical pipeline, led by atumelnant, an oral adrenocorticotropic hormone (ACTH) receptor antagonist currently being studied in Phase III trials for congenital adrenal hyperplasia (CAH). CAH is a rare genetic disorder characterised by impaired cortisol production and excess androgen levels. In Phase II studies, atumelnant demonstrated reductions in androgen biomarkers, including androstenedione and 17-hydroxyprogesterone, while allowing patients to maintain physiologic glucocorticoid replacement therapy. The candidate is also being evaluated in Cushing’s syndrome, another rare endocrine condition. Crinetics’ wider pipeline includes: CRN09682, a Phase I/II programme for neuroendocrine tumours Preclinical programmes targeting Graves’ disease Thyroid eye disease Polycystic kidney disease Obesity Diabetes Vertex expects Palsonify and atumelnant together could generate peak annual revenue exceeding $5 billion. Strengthening Vertex’s M&A Strategy The Crinetics acquisition follows Vertex’s previous major acquisition of Alpine Immune Sciences for $4.9 billion in 2024, which provided the company with povetacicept. Povetacicept, a dual APRIL/BAFF inhibitor, is currently under FDA review for immunoglobulin A nephropathy (IgAN). Vertex has previously highlighted renal disease as a potential future growth driver, with the company suggesting its kidney portfolio could eventually surpass its cystic fibrosis business. Why the Deal Matters The acquisition highlights several important trends across the biopharmaceutical sector: Large pharmaceutical companies continue to use M&A to secure late-stage and commercial assets. Rare diseases remain a major focus for pipeline diversification. Oral therapies are attracting interest as alternatives to injectable treatments. Endocrinology is becoming an increasingly attractive market due to significant unmet medical needs. Summary Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals for approximately $10 billion, gaining access to Palsonify and a broader endocrinology pipeline. The deal strengthens Vertex’s strategy of expanding beyond cystic fibrosis while adding commercial and late-stage rare disease assets across acromegaly, congenital adrenal hyperplasia and other endocrine disorders. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com